Price History

Hover for the daily close. The dotted line marks the period open.

Compare KOD with… →

KOD Key Statistics

As of Sep 4, 2026

Trading

Open: $35.98
Previous Close: $36.36
Day's Range: 35.18–36.62
52-Week Range: 8.91–47.84
Volume: 671.80K
Beta: 2.18

Valuation

Market Cap: $2.22B
P/E Ratio: unprofitable
EPS (ttm): −4.08

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$229.97M
Profit margin: 0.00%
Shares Outstanding: 62.85M
1-Year Return: +313.57%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 677.29K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KOD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+913.38%−91.55%+26.47%

2018*20192020202120222023202420252026*

Year	Return
2026 (partial year)	+26.47%
2025	+181.01%
2024	+227.30%
2023	−57.54%
2022	−91.55%
2021	−42.29%
2020	+104.18%
2019	+913.38%
2018 (partial year)	−30.12%

As of September 4, 2026.

KOD Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$229.97M	—
2024	$0.00	−$176.21M	—
2023	$0.00	−$260.49M	—
2022	$0.00	−$333.82M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$234.39M	−$229.97M	—
2024	$0.00	—	−$186.85M	−$176.21M	—
2023	$0.00	—	−$277.32M	−$260.49M	—
2022	$0.00	—	−$341.38M	−$333.82M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KOD Valuation vs Biotechnology Median

Median of 656 stocks

Metric	KOD	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Kodiak Sciences Inc. (KOD) at $2.22B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 141.

KOD last closed at $35.36 on September 4, 2026. That is −$1.00 (−2.75%) against the previous close. The 52-week range on file runs from $8.91 to $47.84. The latest close sits 296.86% above that 52-week low.

Financial Health

In fiscal 2025, Kodiak Sciences Inc. reported revenue of $0.00. The same year closed with a net loss of $229.97M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −4.08.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +313.57%. Measured over 5 years, that is −17.39% a year compounded. The reported beta is 2.18. Daily returns over the trailing 7 years annualize to a volatility of 105.66%.

Growth & Income

No dividend is on file for KOD.

The strongest complete calendar year on file is 2019 at +913.38%; the weakest is 2022 at −91.55%. Of the 7 complete calendar years on file, 4 finished higher. 2026 is still running; the price is +26.47% year to date.

Peer Comparison

Kodiak Sciences Inc. (KOD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Kodiak Sciences Inc.	KOD	$2.22B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Kodiak Sciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Kodiak Sciences Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Visit website →

Kodiak Sciences Inc. (KOD) Stock Analysis